CMS decided a one-dose gene therapy counts as just a year of treatment when its price is compared with monthly drugs, which ...
The EGFRxMET-targeting bispecific antibody won accelerated approval from the US FDA for head and neck squamous cell carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results